Showing 4791-4800 of 7936 results for "".
- Immune Pharmaceuticals Expands Immuno-Dermatology Development Portfolio With Topical Nano-Formulated Cyclosporine Ahttps://practicaldermatology.com/news/immune-pharmaceuticals-expands-immuno-dermatology-development-portfolio-with-topical-nano-formulated-cyclosporine-a/2458932/Immune Pharmaceuticals Inc. entered into a binding Memorandum of Understanding with Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem regarding the worldwide exclusive licensing and development of a topical, biodegradable, nano-capsule formulation of cyclospo
- FDA Clears Alevicyn SG Antipruritic Spray Gel from Oculus Innovative Scienceshttps://practicaldermatology.com/news/fda-clears-alevicyn-sg-antipruritic-spray-gel-from-oculus-innovative-sciences/2458933/The FDA granted 510(k) clearance to Oculus Innovative Sciences, Inc. for Alevicyn SG Antipruritic Spray Gel with both prescription and over-the-counter indications. The Alevicyn SGprescription product, using Microcyn(R) Technology, is indicate
- Galderma Introduces ASPIRE Loyalty Program for the Aesthetic Industryhttps://practicaldermatology.com/news/galderma-introduces-aspire-loyalty-program-for-the-aesthetic-industry/2458936/Galderma launched ASPIRE Galderma Rewards, a new loyalty program for its aesthetic brands. ASPIRE is unique in that it serves both both US healthcare professionals and consumers in one integrated program. ASPIRE rewards its members with significant savings across the entire aesthetic prod
- InMed Pharmaceuticals Files Provisional Patent for Novel Compounds to Treat Epidermolysis Bullosa Simplexhttps://practicaldermatology.com/news/inmed-pharmaceuticals-files-provisional-patent-for-novel-compounds-to-treat-epidermolysis-bullosa-simplex/2458939/InMed Pharmaceuticals Inc. filed a provisional patent application with the United States Patent and Trademark Office relating to the treatment of Epidermolysis Bullosa Simplex (EBS) using novel formulations of natural cannabinoid compounds developed by InMed. Dr. Sazzad Hossain, InMed Pha
- Encore Dermatology, Inc.: A New Specialty Dermatology Company Launcheshttps://practicaldermatology.com/news/encore-dermatology-inc-a-new-specialty-dermatology-company/2458942/Encore Dermatology, Inc. announced has begun to commercialize Hylatopic®, Tetrix™, and BenzEFoam™, three established topical dermatology products acquired from Valeant Pharmaceuticals North America, LLC and certain of its affiliates. Encore Dermatology, Inc. is a privately
- AbbVie Receives FDA Orphan Drug Designation for Humira for the Investigational Treatment of Moderate-to-Severe Hidradenitis Suppurativahttps://practicaldermatology.com/news/abbvie-receives-fda-orphan-drug-designation-for-humira-for-the-investigational-treatment-of-moderate-to-severe-hidradenitis-suppurativa/2458945/AbbVie announced that the FDA has granted Humira® (adalimumab) orphan drug designation for the investigational treatment of moderate-to-severe hidradenitis suppurativa (HS) (Hurley Stage II and Hurley Stage III disease), a painful, chronic inflammatory skin disease. AbbVie's su
- New Research Finds TriCalm Hydrogel's Itch Relief Superior to Leading OTC Treatmentshttps://practicaldermatology.com/news/new-research-finds-tricalm-hydrogels-itch-relief-superior-to-leading-otc-treatments/2458949/A study conducted to assess the antipruritic effect of over-the-counter (OTC) steroid-free topical hydrogel formulation TriCalm® in reducing itch intensity and duration, has been published in Clinical, Cosmetic, and Investigational Dermatology. The study, which utilized a co
- Viscot Medical Introduces Soffzone Neutral Zone Trayshttps://practicaldermatology.com/news/viscot-medical-introduces-soffzone-neutral-zone-trays/2458950/Intended to reduce the risk of sharps injuries, Viscot Medical’s Soffzone™ Neutral Zone trays were designed by a plastic surgeon for plastic surgeons. According to Viscot, the Soffzone™ Neutral Zone can be easily integrated into a sharps safety
- KYTHERA Biopharmaceuticals Announces FDA Approval of KYBELLA(TM) (also known as ATX-101) -- First and Only Submental Contouring Injectable Drughttps://practicaldermatology.com/news/kythera-biopharmaceuticals-announces-fda-approval-of-kybellatm-also-known-as-atx-101-first-and-only-submental-contouring-injectable-drug/2458953/KYTHERA Biopharmaceuticals, Inc. (Nasdaq:
- Foamix Pharmaceuticals Ltd. Closes Its $69 Million Public Offering of Ordinary Shareshttps://practicaldermatology.com/news/foamix-pharmaceuticals-ltd-closes-its-69-million-public-offering-of-ordinary-shares/2458956/Foamix Pharmaceuticals Ltd. closed its follow-on public offering. A total of 7,419,353 ordinary shares were sold at a price to the public of $9.30 per share. Prior to closing, the underwriters fully exercised their option to purchase 967,741 additional ordinary shares. The net proceeds from the s